CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning balance at Dec. 31, 2022	$ 3	$ 354,752	$ (249,108)	$ 105,647
Beginning balance (in shares) at Dec. 31, 2022	27,425,447
Stockholders' Deficit
Vesting of restricted common stock (in shares)	14,217
Exercise of stock options (in shares)	156
Stock-based compensation expense		1,791		1,791
Net Income (Loss)			(22,646)	(22,646)
Ending balance at Mar. 31, 2023	$ 3	356,543	(271,754)	84,792
Ending balance (in shares) at Mar. 31, 2023	27,439,820
Beginning balance at Dec. 31, 2023	$ 3	362,336	(325,512)	36,827
Beginning balance (in shares) at Dec. 31, 2023	27,607,646
Stockholders' Deficit
Issuance of common stock in connection with the Gilead stock purchase agreement, net of issuance costs (in dollars)		4,308		4,308
Issuance of common stock in connection with the Gilead stock purchase agreement, net of issuance costs (in shares)	6,860,223
Vesting of restricted common stock (in shares)	4,777
Stock-based compensation expense		1,833		1,833
Net Income (Loss)			(17,203)	(17,203)
Ending balance at Mar. 31, 2024	$ 3	$ 368,477	$ (342,715)	$ 25,765
Ending balance (in shares) at Mar. 31, 2024	34,472,646